Top

Published in:

Open Access 01-12-2017 | Research article

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis

Authors: Katia Falasca, Marta Di Nicola, Italo Porfilio, Claudio Ucciferri, Elisabetta Schiaroli, Chiara Gabrielli, Daniela Francisci, Jacopo Vecchiet

Published in: BMC Nephrology | Issue 1/2017

Abstract

Background

Renal dysfunction is a common problem in the HIV+ population, due to the effect of both the HIV virus and the several classes of ARV drugs such as tenofovir (TDF). It is also known that the presence of renal damage correlates with cardiovascular risk and therefore with the risk of mortality of the patients accordingly. The detection of early renal damage is very important. Albuminuria and microalbuminuria are markers of early kidney disease and cardiovascular risk. The aim of the study is to evaluate the prevalence of microalbuminuria in a large polycentric sample, of unselected and consecutive HIV-patients followed as outpatients, and to assess its association with different therapeutic regimens.

Methods

We studied 326 patients with a mean age of 48.4 ± 1.6 years, treated at the Infectious Diseases Clinics of Chieti and Perugia for 48 weeks. The main metabolic parameters and the microalbuminuria levels in a single sample of urine were evaluated.

Results

Microalbuminuria was detected in 61.0% of patients at T0 and in 49.7% after 48 weeks of observation with a median values of 1.1 mg/L (IQR: 0-2.7) vs. 0 mg/L (IQR: 0-2.0). 70% of the enrolled population did not show changes in microalbuminuria levels over time, 19% showed improvement, and 11% of the population had a worsening of microalbuminuria levels without any alteration of creatinine, uric acid and GFR-MDRD. We also found a statistically significant association between the development of microalbuminuria and gender (p < 0.035), Arterial Hypertension (AH) (p < 0.028) and therapy with TDF (p < 0.050).

Conclusion

We showed a very high prevalence of microalbuminuria, much higher than the literature data; the use of TDF affects the renal function in a statistically significant way and should therefore be considered a risk factor for kidney damage, which can be early assessed with the measurement of microalbuminuria.

Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17(5):491–501.CrossRefPubMed

Phair J, Palella F. Renal disease in HIV-infected individuals. Curr Opin HIV AIDS. 2011;6(4):285–9.CrossRefPubMedPubMedCentral

Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, et al. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–93.CrossRefPubMed

Mateen FJ, Kanters S, Kalyesubula R, Mukasa B, Kawuma E, Kengne AP, Mills EJ. Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda. J Hypertens. 2013;31(7):1372–8. discussion 1378CrossRefPubMed

Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis. 2004;23(8):625–30.CrossRefPubMed

Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep. 2010;12(5):364–8.CrossRefPubMedPubMedCentral

Lemley KV, Abdullah I, Myers BD, Meyer TW, Blouch K, Smith WE, Bennett PH, Nelson RG. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int. 2000;58(3):1228–37.CrossRefPubMed

Wang Y, Yuan A, Yu C. Correlation between microalbuminuria and cardiovascular events. Int J Clin Exp Med. 2013;6(10):973–8.PubMedPubMedCentral

Hadigan C, Edwards E, Rosenberg A, Purdy JB, Fleischman E, Howard L, Mican JM, Sampath K, Oyalowo A, Johnson A, et al. Microalbuminuria in HIV disease. Am J Nephrol. 2013;37(5):443–51.CrossRefPubMed

10.

Schneider A, Jardine AG, Schneider MP, Holdaas H, Holme I, Fellstroem BC, Zannad F, Schmieder RE, Group AS. Determinants of cardiovascular risk in haemodialysis patients: post hoc analyses of the AURORA study. Am J Nephrol. 2013;37(2):144–51.CrossRefPubMed

11.

Choi EK, Shen MJ, Han S, Kim D, Hwang S, Sayfo S, Piccirillo G, Frick K, Fishbein MC, Hwang C, et al. Intrinsic cardiac nerve activity and paroxysmal atrial tachyarrhythmia in ambulatory dogs. Circulation. 2010;121(24):2615–23.CrossRefPubMedPubMedCentral

12.

Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, Fields TA, Svetkey LP, Flanagan KH, Klotman PE, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66(3):1145–52.CrossRefPubMed

13.

Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, D'Agati VD. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009;75(4):428–34.CrossRefPubMed

14.

Mpondo BC, Kalluvya SE, Peck RN, Kabangila R, Kidenya BR, Ephraim L, Fitzgerald DW, Downs JA. Impact of antiretroviral therapy on renal function among HIV-infected Tanzanian adults: a retrospective cohort study. PLoS One. 2014;9(2):e89573.CrossRefPubMedPubMedCentral

15.

Campbell LJ, Dew T, Salota R, Cheserem E, Hamzah L, Ibrahim F, Sarafidis PA, Moniz CF, Hendry BM, Poulton M, et al. Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol. 2012;13:85.CrossRefPubMedPubMedCentral

16.

Maggi P, Montinaro V, Bellacosa C, Pietanza S, Volpe A, Graziano G, Strippoli GF, Angarano G. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDs. 2012;26(1):5–11.CrossRefPubMed

17.

Giacomet V, Erba P, Di Nello F, Coletto S, Vigano A, Zuccotti G. Proteinuria in paediatric patients with human immunodeficiency virus infection. World J Clin Cases. 2013;1(1):13–8.CrossRefPubMedPubMedCentral

18.

Vogt L, Navis G, Koster J, Manolis AJ, Reid JL, de Zeeuw D, Angiotensin IIRATMiISHSG. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005;23(11):2055–61.CrossRefPubMed

19.

Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res. 2006;29(8):567–72.CrossRefPubMed

20.

Shabbal DM, Jamda MA, Dalhatu IT, Abdulrahman MB, Isichei C. Comparison of microalbuminuria among treatment naive HIV sero-positive and negative adult clients in faith alive foundation hospital, Jos. Niger Med J. 2014;55(6):508–11.CrossRefPubMedPubMedCentral

21.

Masimango MI, Sumaili EK, Jadoul M, Wallemacq P, Mubagwa DK, Makulo RJ, Lepira FB, Nseka NM. Prevalence of microalbuminuria and diagnostic value of dipstick proteinuria in outpatients from HIV clinics in Bukavu, the Democratic Republic of Congo. BMC Nephrol. 2014;15:146.CrossRefPubMedPubMedCentral

22.

Baekken M, Os I, Sandvik L, Oektedalen O. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant. 2008;23(10):3130–7.CrossRefPubMedPubMedCentral

23.

Kabanda A, Vandercam B, Bernard A, Lauwerys R, van Ypersele de Strihou C. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis. 1996;27(6):803–8.CrossRefPubMed

24.

Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, Wohl D, Shlipak MG. Microalbuminuria in HIV infection. AIDS. 2007;21(8):1003–9.CrossRefPubMedPubMedCentral

25.

Vigano A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S, Beretta S, Rombola G, Mora S. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig. 2007;27(8):573–81.CrossRefPubMed

26.

Overton ET, Patel P, Mondy K, Bush T, Conley L, Rhame F, Kojic EM, Hammer J, Henry K, Brooks JT, et al. Cystatin C and baseline renal function among HIV-infected persons in the SUN study. AIDS Res Hum Retroviruses. 2012;28(2):148–55.CrossRefPubMed

27.

Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790.PubMedPubMedCentral

28.

Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24(10):1519–27.CrossRefPubMedPubMedCentral

29.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:a:D study. J Infect Dis. 2013;207(9):1359–69.CrossRefPubMedPubMedCentral

30.

Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22(12):731–6.CrossRefPubMed

31.

Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010;121(5):651–8.CrossRefPubMedPubMedCentral

32.

Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26(15):1917–26.CrossRefPubMed

33.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte A, Kirk O, Ryom L, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23–32.CrossRefPubMed

34.

Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Eur Rev Med Pharmacol Sci. 2012;16(4):491–8.PubMed

35.

Ucciferri C, Falasca K, Mancino P, Pizzigallo E, Vecchiet J. Proteinuria in an African HIV-infected patient: effects of telmisartan. Infez Med. 2011;19(2):125–7.PubMed

36.

Ucciferri C, Falasca K, Vignale F, Di Nicola M, Vecchiet J. Long term effect of telmisartan in HIV-positive male patients with high blood pressure. Braz J Infect Dis. 2015;19(6):668–9.CrossRefPubMed

37.

Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, De Caterina R. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther. 2011;16(5):639–45.CrossRefPubMed

38.

Ng WY, Lui KF, Thai AC. Evaluation of a rapid screening test for microalbuminuria with a spot measurement of urine albumin-creatinine ratio. Ann Acad Med Singap. 2000;29(1):62–5.PubMed

39.

Parikh CR, Fischer MJ, Estacio R, Schrier RW. Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity. Nephrol Dial Transplant. 2004;19(7):1881–5.CrossRefPubMed

40.

Falasca K, Ucciferri C, Mancino P, Di Iorio A, Vignale F, Pizzigallo E, Vecchiet J. Cystatin C, adipokines and cardiovascular risk in HIV infected patients. Curr HIV Res. 2010;8(5):405–10.CrossRefPubMed

41.

de Geus HR, Woo JG, Wang Y, Devarajan P, Betjes MG, le Noble JL, Bakker J. Urinary Neutrophil Gelatinase-associated Lipocalin measured on admission to the intensive care unit accurately discriminates between sustained and transient acute kidney injury in adult critically ill patients. Nephron Extra. 2011;1(1):9–23.CrossRefPubMedPubMedCentral

Title: Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
Authors: Katia Falasca
Marta Di Nicola
Italo Porfilio
Claudio Ucciferri
Elisabetta Schiaroli
Chiara Gabrielli
Daniela Francisci
Jacopo Vecchiet
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-017-0672-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Urinary TIMP-2 and IGFBP7 for the prediction of acute kidney injury following cardiac surgery

Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)

Risk factors for developing acute kidney injury in older people with diabetes and community-acquired pneumonia: a population-based UK cohort study

Acute kidney injury as an independent risk factor for unplanned 90-day hospital readmissions

The impact of continuous renal replacement therapy on renal outcomes in dialysis-requiring acute kidney injury may be related to the baseline kidney function

Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page